文献速递糖尿病骨质疏松与钙磷/甲状旁腺

老年2型糖尿病患者的血糖控制、磺脲类药物与胰岛素治疗及跌倒和骨折风险:一项观察性研究

Glucose Control, Sulfonylureas, and Insulin Treatment in Older Adults With Type 2 Diabetes and Risk of Falls and Fractures: An Observational Study.
PubMed 文献 · Diabetes Care · 2025-01-01

该观察性队列研究利用英国临床实践研究数据链GOLD数据,纳入2000至2017年≥70岁2型糖尿病患者,暴露组为连续三次HbA1c<7%(53 mmol/mol)且使用胰岛素或磺脲类药物者,按1:3匹配非暴露组。结果显示,暴露组因跌倒和骨折住院的相对风险略高但未达统计学显著(HR 1.04 [95% CI 0.96-1.11] 和 1.07 [95% CI 0.97-1.17]),10年绝对风险差异微小。结论认为无证据表明持续HbA1c<7%的胰岛素或磺脲类治疗与临床有意义的跌倒或骨折风险增加相关。

要点

  • 在≥70岁2型糖尿病患者中,持续HbA1c<7%且使用胰岛素或磺脲类药物与跌倒住院风险无显著关联(HR 1.04 [95% CI 0.96-1.11])。
  • 该暴露与骨折住院风险亦无显著关联(HR 1.07 [95% CI 0.97-1.17])。
  • 10年跌倒住院绝对风险在暴露组为15.6-36.8%(70-85岁),非暴露组为15.1-36.0%,绝对风险差异微小。

核心结论

  • 未发现持续HbA1c<7%同时接受胰岛素或磺脲类治疗的老年2型糖尿病患者与临床有意义的跌倒或骨折风险增加相关的证据。
  • 临床医生应继续在老年2型糖尿病患者中平衡血糖控制的获益与并发症风险。

研究设计与样本

  • 观察性队列研究,使用英国临床实践研究数据链GOLD数据,链接医院和死亡记录。
  • 纳入2000至2017年间≥70岁的2型糖尿病患者,暴露定义为连续三次HbA1c测量<7%(53 mmol/mol)且接受胰岛素或磺脲类治疗。
  • 每名暴露个体与三名非暴露个体匹配。
  • 共纳入21,365名个体,其中暴露组5,833人(27.3%)。
  • 采用灵活参数生存模型,调整社会人口学和临床因素,估计相对风险(风险比[HR])和绝对风险。

主要发现

  • 暴露组因跌倒住院的调整后相对风险与非暴露组相比略高但未达统计学显著(HR 1.04 [95% CI 0.96-1.11])。
  • 暴露组因骨折住院的调整后相对风险与非暴露组相比略高但未达统计学显著(HR 1.07 [95% CI 0.97-1.17])。
  • 10年跌倒住院绝对风险在暴露组为15.6-36.8%(70-85岁),非暴露组为15.1-36.0%。
  • 绝对风险差异微小:5年时为0.2-0.6%,10年时为0.5-0.8%。

临床怎么用

  • 临床医生应继续在老年2型糖尿病患者中平衡血糖控制的获益与并发症风险。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To estimate the association among glucose control, sulfonylureas, and insulin treatment with the risk of hospitalization for falls and fractures in older adults with type 2 diabetes (T2D). RESEARCH DESIGN AND METHODS: This observational cohort study used U.K. Clinical Practice Research Datalink GOLD data linked to hospital and death records. Older adults (≥70 years) with T2D, identified between 2000 and 2017, were considered exposed if they had three consecutive HbA1c measurements <7% (53 mmol/mol) while receiving treatment with insulin or sulfonylureas. Each exposed individual was matched with to three nonexposed individuals. Outcomes included hospitalizations for falls and fractures. Flexible parametric survival models, adjusted for sociodemographic and clinical factors, and associated estimated relative (hazard ratio [HR]) and absolute risks. RESULTS: Among 21,365 individuals (n = 5,833 [27.3%] in the exposed group), the adjusted relative risks of hospitalization for falls and fractures were marginally higher compared with those nonexposed (HR 1.04 [95% CI 0.96-1.11] and 1.07 [95% CI 0.97-1.17], respectively). The 10-year absolute risk values of hospitalization for falls were slightly higher in the exposed (range 15.6-36.8% in those aged 70-85 years) than nonexposed (15.1-36.0%) individuals. Absolute risk differences remained minimal (0.2-0.6% at 5 years and 0.5-0.8% at 10 years). CONCLUSIONS: We found no evidence of an association between sustained HbA1c <7% while receiving insulin or sulfonylurea therapy and clinically meaningful increased risks of falls or fractures in older adults with T2D. Clinicians should continue to balance the benefits of glycemic control with the risks of complications in older adults.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Shabnam S, Ling S, Gillies C, et al. Glucose Control, Sulfonylureas, and Insulin Treatment in Older Adults With Type 2 Diabetes and Risk of Falls and Fractures: An Observational Study. Diabetes Care. 2025. PMID: 40532134. doi:10.2337/dc25-0517

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。